Table 2.
Hazard ratio of cancers in all patients with myeloproliferative neoplasms compared to matched controls. MPN=myeloproliferative neoplasm, HR=hazard ratio, CI=confidence interval
| Type of cancer |
HR | 95% CI | Number of events in MPN patients |
|---|---|---|---|
| All non-hematologic | 1.6 | 1.5 - 1.7 | 1185 |
| Non-melanoma skin cancer | 2.8 | 2.4 - 3.3 | 252 |
| Brain | 2.8 | 1.9 - 4.2 | 37 |
| Kidney | 2.8 | 2.0 - 4.0 | 49 |
| Endocrine organs | 2.5 | 1.6 - 3.8 | 33 |
| Malignant melanoma | 1.9 | 1.4 - 2.7 | 53 |
| Pancreas | 1.8 | 1.2 - 2.6 | 32 |
| Lung | 1.7 | 1.4 - 2.2 | 92 |
| Head and neck | 1.7 | 1.2 - 2.7 | 32 |
| Esophagus and stomach | 1.6 | 1.2 - 2.2 | 53 |
| Breast | 1.4 | 1.1 - 1.7 | 106 |
| Prostate | 1.2 | 1.1 - 1.4 | 190 |
| Liver and gallbladder | 1.3 | 0.9 - 1.9 | 31 |
| Colon, rectum, and anus | 1.1 | 0.9 - 1.3 | 129 |
| Female genital organs | 1.2 | 0.9 - 1.5 | 73 |
| Urinary tract excluding kidney | 1 | 0.7 - 1.3 | 46 |